Intensive insulin therapy and pentastarch resuscitation in severe sepsis

New England Journal of Medicine

Volumn 358, Issue 2, 2008, Pages 125-139

  Brunkhorst, Frank M ^a   Engel, Christoph ^b   Bloos, Frank ^a   Meier Hellmann, Andreas ^c   Ragaller, Max ^d   Weiler, Norbert ^e   Moerer, Onnen ^f   Gruendling, Matthias ^g   Oppert, Michael ^h   Grond, Stefan ⁱ   Olthoff, Derk ^j   Jaschinski, Ulrich ^k   John, Stefan ^l   Rossaint, Rolf ^m   Welte, Tobias ^n,o   Schaefer, Martin ^p   Kern, Peter ^q   Kuhnt, Evelyn ^b   Kiehntopf, Michael ^a   Hartog, Christiane ^a   Natanson, Charles ^r   Loeffler, Markus ^b   Reinhart, Konrad ^a   more..

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^j UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^k KLINIKUM AUGSBURG   (Germany)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^m UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁿ OTTO VON GUERICKE UNIVERSITY   (Germany)

^o HANNOVER MEDICAL SCHOOL   (Germany)

^p Klinikum Brandenburg   (Germany)

^q ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^r NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; INSULIN; MONOCOMPONENT INSULIN; RINGER LACTATE SOLUTION; ANTIDIABETIC AGENT; ISOTONIC SOLUTION; RINGER'S SOLUTION; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FLUID RESUSCITATION; HUMAN; HYPOGLYCEMIA; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SEPSIS; SURVIVAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CRITICAL ILLNESS; DOSE RESPONSE; FLUID THERAPY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; RISK FACTOR; TREATMENT FAILURE;

AGED; COMBINED MODALITY THERAPY; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUID THERAPY; HETASTARCH; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; ISOTONIC SOLUTIONS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEPSIS; TREATMENT FAILURE;

EID: 38049096093     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa070716     Document Type: Article

References (37)

1. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
2. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
3. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73. [Errata, Crit Care Med 2004;32:1448, 2169-70.]
4. Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004;4:CD000567.
5. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Schildberg FW, Menger MD. Hydroxyethyl starch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia. Anesthesiology 2002;97:460-70.
6. Morisaki H, Bloos F, Keys J, Martin C, Neal A, Sibbald WJ. Compared with crystalloid, colloid therapy slows progression of extrapulmonary tissue injury in septic sheep. J Appl Physiol 1994;77:1507-18.
7. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004;139:552-63.
8. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 2001;72:527-33.
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
10. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003;31:359-66.
11. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
12. What is a serious adverse event? Rockville, MD: MedWatch, FDA Safety Information and Adverse Event Reporting Program, 2004. (Accessed December 14, 2007, at http://www.fda.gov/medwatch/report/DESK/advevnt.htm.)
13. Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: results of a prospective, multicentre study. Intensive Care Med 1999;25:686-96.
14. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-41.
15. Brunkhorst FM, Kuhnt E, Engel C, et al. Intensive insulin therapy in patients with severe sepsis and septic shock is associated with an increased rate of hypoglycemia: results from a randomized multicenter study (VISEP). Infection 2005;33:Suppl 1:19.
16. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004;350:2272-9.
17. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care 2007;30:1005-11.
18. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-52.
19. Winkelmayer WC, Glynn RJ, Levin R, Avorn J. Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 2003;64:1046-9.
20. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2.
21. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6.
22. Wiesen P, Canivet JL, Ledoux D, Roediger L, Damas P. Effect of hydroxyethylstarch on renal function in cardiac surgery: a large scale retrospective study. Acta Anaesthesiol Belg 2005;56:257-63.
23. Liet JM, Bellouin AS, Boscher C, Lejus C, Rozé JC. Plasma volume expansion by medium molecular weight hydroxyethyl starch in neonates: a pilot study. Pediatr Crit Care Med 2003;4:305-7.
24. Beyer R, Harmening U, Rittmeyer O, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br J Anaesth 1997;78:44-50.
25. Vogt N, Bothner U, Brinkmann A, de Petriconi R, Georgieff M. Peri-operative tolerance to large-dose 6% HES 200/0.5 in major urological procedures compared with 5% human albumin. Anaesthesia 1999;54:121-7.
26. Arellano R, Gan BS, Salpeter MJ, et al. A triple-blinded randomized trial comparing the hemostatic effects of large-dose 10% hydroxyethyl starch 264/0.45 versus 5% albumin during major reconstructive surgery. Anesth Analg 2005;100:1846-53.
27. Sakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216-24.
28. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003;325:349-62.
29. Haynes GR, Havidich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 2004;101:560-1.
30. Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001;345:622-3.
31. Legendre C, Thervet E, Page B, Percheron A, Noël LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9.
32. Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5:1120-9.
33. van Rijen EA, Ward JJ, Little RA. Effects of colloidal resuscitation fluids on reticuloendothelial function and resistance to infection after hemorrhage. Clin Diagn Lab Immunol 1998;5:543-9.
34. Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001;35:726-32.
35. Auwerda JJ, Wilson JH, Sonneveld P. Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 2002;137:1013-4.
36. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus - an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006;77:83-5.
37. Wiedermann CJ. Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr 2004;116:583-94.